Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SANTA CLARA, Calif., July 13, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research, has released another substantial collection of life science products to its e-commerce platform.
CrownBio will add a significant number of cell lines and reference standards related to EGFR, KRAS, and BRAF signaling cascades of the MAPK pathway, which plays a critical role in the development and progression of cancer. Further enhancements to the CrownBio catalog also include additional monoclonal antibodies to immune checkpoint and cancer-related targets, as well as compounds to activate or inhibit signaling pathways.
This product expansion further strengthens CrownBio’s current product offerings within preclinical drug discovery and cancer research which already includes antibodies for in vivo and in vitro studies, recombinant proteins, recombinant cell lines, tumor samples for oncology research and development, and tumor tissue microarrays.
“The expansion of products validates our commitment to offer a complementary set of reagents, while further broadening the breath of products available from CrownBio. Furthermore, we have extended our customer service hours for more immediate and convenient access to our product support,” commented Debby Saunders, Executive Director of Life Science Development at CrownBio.
“We are very pleased with the growth of the life science division,” stated Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. “The division continues to demonstrate significant growth, we remain committed to providing products that meet our customers need and a method to access them quickly and easily.”
CrownBio’s online store can be accessed via: https://www.crownbio.com/shop.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
